Retatrutide, a novel dual stimulator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising data in early clinical assessments . Ongoing https://pageoftoday.com/story6863535/retatrutide-emerging-studies-and-possible-therapeutic-roles